On July 7, digital pharmaceutical company Welt (WELT) marked its 10th anniversary by announcing its ambition to become a "digital convergence pharmaceutical" company, connecting AI and pharmaceuticals.


Founded in 2016, Welt is a medical AI company that spun off from Samsung Electronics. The company has developed technology that links patient data from daily life to medical care. In 2023, Welt received approval from the Ministry of Food and Drug Safety for SleepQ, a digital therapeutic for insomnia, establishing itself as a leader in the digital therapeutics sector. More recently, it has introduced a new treatment paradigm centered on its AI agent 'Dr. SAM' and the 'DrugOS™' platform.

AI-Based Health Management Service 'Dr. Saem'. WELT

AI-Based Health Management Service 'Dr. Saem'. WELT

View original image

The digital convergence pharmaceuticals proposed by Welt are an innovative concept in which AI agents are integrated with already-prescribed medications. These agents provide medication guidance, lifestyle coaching, side effect monitoring, adherence management, and continuous communication with healthcare professionals, thereby enhancing the therapeutic efficacy of pharmaceuticals. Welt aims to usher in an era where AI is involved in every step of the treatment process, from the moment a prescription is issued at the hospital to the next outpatient visit.


This vision is made possible by Welt’s proprietary platform technology, DrugOS™. DrugOS is a platform similar to a "residency program," where AI agents observe, learn from, and grow with actual patients. Within DrugOS, the AI agent internalizes a vast array of medical knowledge and the latest clinical evidence, and is continually evaluated in real-world settings. Through this learning process, the AI evolves beyond simply being "book smart"—possessing extensive medical knowledge—and becomes "clinically smart," meaning it can communicate and assist more appropriately in real medical environments.


Sungji Kang, CEO of Welt, is discussing under the theme "Protecting Mental Health through Digital Means" at the "2025 Good Brain Conference" hosted by The Asia Business Daily at Westin Chosun Hotel in Jung-gu, Seoul on September 3rd, 2025. Photo by Jinhyung Kang

Sungji Kang, CEO of Welt, is discussing under the theme "Protecting Mental Health through Digital Means" at the "2025 Good Brain Conference" hosted by The Asia Business Daily at Westin Chosun Hotel in Jung-gu, Seoul on September 3rd, 2025. Photo by Jinhyung Kang

View original image

In addition, Welt’s AI agent is designed to be proactive, not merely waiting for patient questions, but monitoring changes in the patient's condition and initiating conversations when needed. This approach enables early detection of symptom changes and provides a new healthcare experience by connecting patients and healthcare providers.


Such technology is opening new possibilities in the pharmaceutical industry. While drug development has traditionally been at the center of therapeutic innovation, AI now represents a new axis of innovation by enhancing the efficacy and patient experience of already-approved medications. In practice, Welt is pursuing joint development and licensing collaborations on digital convergence pharmaceuticals with domestic and international pharmaceutical companies, expanding its business beyond Korea to global markets such as Germany and the United States.



CEO Seongji Kang stated, "The next decade will be an era in which all pharmaceuticals become smarter through AI. Under Welt's mission of 'Software will treat the world,' our next goal is to create a world where everyone, everywhere, can access healthcare services through AI."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing